Drug firm Cipla Ltd. on Wednesday said that the US health regulator has issued a warning letter to the company for its manufacturing facility in Goa.
“Further to our earlier communication on the Goa manufacturing facility inspection conducted from September 16-27, 2019 by the United States Food and Drug Administration (USFDA), the company has received a warning letter from USFDA,” Cipla Ltd. said.
The company further said that it remains committed to maintain highest standards of compliance and will work closely with the agency to comprehensively address all the observations.
Shares of Cipla were trading at ₹418.30 a piece on Bombay Stock Exchange (BSE) in the morning trade on BSE, down 1.66% from its previous close.
You have reached your limit for free articles this month.
Register to The Hindu for free and get unlimited access for 30 days.
Subscription Benefits Include
Today's Paper
Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.
Unlimited Access
Enjoy reading as many articles as you wish without any limitations.
Personalised recommendations
A select list of articles that match your interests and tastes.
Faster pages
Move smoothly between articles as our pages load instantly.
Dashboard
A one-stop-shop for seeing the latest updates, and managing your preferences.
Briefing
We brief you on the latest and most important developments, three times a day.
Not convinced? Know why you should pay for news.
*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.
